Literature DB >> 35106126

Bioengineered pseudovirus nanoparticles displaying the HA1 antigens of influenza viruses for enhanced immunogenicity.

Ming Xia1, Md Rejaul Hoq2, Pengwei Huang1, Wen Jiang2, Xi Jiang1,3, Ming Tan1,3.   

Abstract

Even with implementation of current influenza vaccines, influenza still claims up to 500,000 lives worldwide annually, indicating a need for a better vaccine strategy. We have developed a technology to generate unique S60-HA1 pseudovirus nanoparticles (PVNPs) that display the receptor-binding HA1 domains of influenza viruses. Each self-assembled S60-HA1 PVNP consists of a T = 1 icosahedral S60 nanoparticle that resembles the inner shell of norovirus capsid and 60 surface-displayed HA1 antigens that are excellent vaccine targets. Soluble S60-HA1 PVNPs presenting HA1 antigens of H7N9 influenza virus subtypes have been produced efficiently in large amount. Their three-dimensional (3D) structures have been solved by cryogenic electron microscopy. The PVNP-displayed HA1 antigens react with HA-specific antibody, and retain authentic sialic acid binding specificity and hemagglutinate human erythrocytes. The PVNPs are highly immunogenic, eliciting high titers of HA1-specific antibodies in mice and the mouse sera strongly inhibited hemagglutinations of homologous and heterologous influenza virus HA proteins. Therefore, the S60-HA1 PVNPs may provide useful reagents to study influenza viruses and offer a potential new vaccine tactic to fight the deadly influenza disease. © Tsinghua University Press and Springer-Verlag GmbH Germany, part of Springer Nature 2021.

Entities:  

Keywords:  S60 nanoparticle; hemagglutinin; influenza vaccine; influenza virus; norovirus; pseudovirus nanoparticle

Year:  2022        PMID: 35106126      PMCID: PMC8795936          DOI: 10.1007/s12274-021-4011-x

Source DB:  PubMed          Journal:  Nano Res        ISSN: 1998-0000            Impact factor:   10.269


  46 in total

1.  The p domain of norovirus capsid protein forms a subviral particle that binds to histo-blood group antigen receptors.

Authors:  Ming Tan; Xi Jiang
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

Review 2.  The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza.

Authors:  Marc-André D'Aoust; Manon M-J Couture; Nathalie Charland; Sonia Trépanier; Nathalie Landry; Frédéric Ors; Louis-P Vézina
Journal:  Plant Biotechnol J       Date:  2010-02-18       Impact factor: 9.803

3.  Polyvalent complexes for vaccine development.

Authors:  Leyi Wang; Pengwei Huang; Hao Fang; Ming Xia; Weiming Zhong; Monica M McNeal; Xi Jiang; Ming Tan
Journal:  Biomaterials       Date:  2013-03-15       Impact factor: 12.479

4.  Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies.

Authors:  Masaru Kanekiyo; Chih-Jen Wei; Hadi M Yassine; Patrick M McTamney; Jeffrey C Boyington; James R R Whittle; Srinivas S Rao; Wing-Pui Kong; Lingshu Wang; Gary J Nabel
Journal:  Nature       Date:  2013-05-22       Impact factor: 49.962

5.  Effects of Influenza Vaccination in the United States During the 2017-2018 Influenza Season.

Authors:  Melissa A Rolfes; Brendan Flannery; Jessie R Chung; Alissa O'Halloran; Shikha Garg; Edward A Belongia; Manjusha Gaglani; Richard K Zimmerman; Michael L Jackson; Arnold S Monto; Nisha B Alden; Evan Anderson; Nancy M Bennett; Laurie Billing; Seth Eckel; Pam Daily Kirley; Ruth Lynfield; Maya L Monroe; Melanie Spencer; Nancy Spina; H Keipp Talbot; Ann Thomas; Salina M Torres; Kimberly Yousey-Hindes; James A Singleton; Manish Patel; Carrie Reed; Alicia M Fry
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 20.999

6.  Structure determination of feline calicivirus virus-like particles in the context of a pseudo-octahedral arrangement.

Authors:  Wim P Burmeister; Marlyse Buisson; Leandro F Estrozi; Guy Schoehn; Olivier Billet; Zahia Hannas; Cécile Sigoillot; Hervé Poulet
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

7.  Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses.

Authors:  Masaru Kanekiyo; M Gordon Joyce; Rebecca A Gillespie; John R Gallagher; Sarah F Andrews; Hadi M Yassine; Adam K Wheatley; Brian E Fisher; David R Ambrozak; Adrian Creanga; Kwanyee Leung; Eun Sung Yang; Seyhan Boyoglu-Barnum; Ivelin S Georgiev; Yaroslav Tsybovsky; Madhu S Prabhakaran; Hanne Andersen; Wing-Pui Kong; Ulrich Baxa; Kathryn L Zephir; Julie E Ledgerwood; Richard A Koup; Peter D Kwong; Audray K Harris; Adrian B McDermott; John R Mascola; Barney S Graham
Journal:  Nat Immunol       Date:  2019-02-11       Impact factor: 25.606

8.  Development and evaluation of two subunit vaccine candidates containing antigens of hepatitis E virus, rotavirus, and astrovirus.

Authors:  Ming Xia; Chao Wei; Leyi Wang; Dianjun Cao; Xiang-Jin Meng; Xi Jiang; Ming Tan
Journal:  Sci Rep       Date:  2016-05-19       Impact factor: 4.379

9.  Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains.

Authors:  Seth J Zost; Kaela Parkhouse; Megan E Gumina; Kangchon Kim; Sebastian Diaz Perez; Patrick C Wilson; John J Treanor; Andrea J Sant; Sarah Cobey; Scott E Hensley
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-06       Impact factor: 11.205

10.  A naturally protective epitope of limited variability as an influenza vaccine target.

Authors:  Craig P Thompson; José Lourenço; Adam A Walters; Uri Obolski; Matthew Edmans; Duncan S Palmer; Kreepa Kooblall; George W Carnell; Daniel O'Connor; Thomas A Bowden; Oliver G Pybus; Andrew J Pollard; Nigel J Temperton; Teresa Lambe; Sarah C Gilbert; Sunetra Gupta
Journal:  Nat Commun       Date:  2018-09-21       Impact factor: 14.919

View more
  1 in total

1.  A biepitope, adjuvant-free, self-assembled influenza nanovaccine provides cross-protection against H3N2 and H1N1 viruses in mice.

Authors:  Yongbo Qiao; YaXin Zhang; Jie Chen; Shenghui Jin; Yaming Shan
Journal:  Nano Res       Date:  2022-07-01       Impact factor: 10.269

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.